Aesthetic medicine carries the heaviest marketing risk in the regenerative space. This dermatologist adipose banking guide maps the line between an established surgical procedure and an unapproved biological drug, a line drawn by processing and by advertising rather than by specialty. It also covers what recent FDA enforcement turned on and what the FTC expects.
TLDR: Autologous fat grafting for contour is long standing surgical practice. Two moves change the federal analysis: enzymatic digestion of the tissue to isolate cells, and marketing an adipose-derived product for skin quality, wrinkles, or scarring. Either can defeat minimal manipulation or homologous use under 21 CFR 1271.10(a) and move the product into the 351 drug pathway, which requires an IND to study it and a BLA to market it. Recent FDA warning letters turned on those points. Banking is storage, and it does not guarantee eligibility, access, or clinical benefit.
Important Disclaimer: Save My Fat is a connector linking patients and providers to a United States tissue bank. Save My Fat does not provide FDA-approved treatments or cures and does not guarantee eligibility, access, or clinical benefit. No adipose-derived product is FDA approved for any dermatologic or aesthetic indication. This article is written for licensed clinicians for educational purposes only and is not legal advice, and patients should consult their own licensed healthcare professionals before deciding about banking.
Fat grafting has a long track record in dermatologic and plastic surgery, and the federal questions do not arise from the harvest or the injection. They arise from what happens to the tissue in between, and from what the practice website says it is for.
That second point is where dermatology practices get exposed. Aesthetic marketing is visual and claim heavy, and FDA reads advertising as evidence of intended use. A page promising smoother texture or softer scars does not read to a regulator as marketing. It reads as a statement of intended use.
Where Fat Grafting Ends and Drug Regulation Begins
Human cells, tissues, and cellular and tissue-based products fall under 21 CFR Part 1271. A product meeting all four criteria in section 1271.10(a) is regulated solely as a 361 HCT/P. Miss even one and it becomes a 351 product, a biological drug requiring an IND before human study and a BLA before marketing.
Same-day autologous fat transfer for contour generally fits the tissue framework. Tissue is harvested, minimally handled, and returned to the same patient for a structural purpose. Two moves change that: enzymatic digestion with collagenase to isolate the stromal vascular fraction, and a stated purpose unrelated to the structural function fat serves natively.
The Four Criteria in 21 CFR 1271.10(a), Applied to Adipose
Providers often assume autologous use settles the question. It does not. All four criteria must be met at once, and in aesthetics the first two are usually the ones that fail, as set out at 21 CFR 1271.10(a).
| Criterion | What the regulation requires | Where aesthetic workflows are exposed |
|---|---|---|
| Minimal manipulation | Processing must not alter the relevant biological characteristics of cells, or the original relevant characteristics of structural tissue | Collagenase digestion to isolate stromal vascular fraction |
| Homologous use only | Intended use is judged by labeling, advertising, and other indications of objective intent | Advertising for skin quality, wrinkles, or scar appearance states a non-structural purpose |
| No prohibited combination | No combination with another article except water, crystalloids, or a sterilizing, preserving, or storage agent | Carriers, growth factor preparations, or other actives added to the product |
| Systemic effect and metabolic dependence | No systemic effect and no dependence on living cell metabolic activity, or such an effect with autologous, first or second degree relative, or reproductive use | Autologous use satisfies this one, which is why practices assume the rest is satisfied |
Clearing the fourth criterion is no defense to failing the first or second. FDA’s minimal manipulation guidance, finalized in July 2020, is the document to read before a service page goes live.
What the Recent Warning Letters Actually Turned On
Enforcement shows how FDA applies these criteria. Three recent letters are worth reading in full. The products were umbilical cord derived, not adipose, but the reasoning is source agnostic.
| Recipient and date | What FDA cited |
|---|---|
| Dynamic Stem Cell Therapy, February 11, 2026 | Unapproved new drug and unlicensed biological product, more than minimal manipulation, non-homologous use for cardiovascular disease and arthritis, misbranding under 502(f)(1), exosome marketing flagged |
| Innate Healthcare Institute, August 15, 2025 | Umbilical cord mesenchymal stromal cell product, minimal manipulation failure, non-homologous use including intended treatment of autism, no BLA, misbranding |
| Supreme Rejuvenation, May 5, 2025 | Exosome products marketed as unapproved new drugs and unlicensed biologics |
Read these as the operating baseline, not as scare material. In the first two, a processed cell product plus a clinical purpose the tissue does not serve natively added up to a drug.
Exosomes Are the Most Common Aesthetic Exposure
Exosome marketing is widespread in aesthetics, and the status is not ambiguous. FDA’s consumer alert on regenerative products states that blood-forming stem cells from cord blood are the only approved stem cell products and that no exosome product is FDA approved.
The Supreme Rejuvenation letter is the clean illustration, because it turned on exosome products as unapproved drugs rather than on the 1271.10(a) criteria. A practice can be disciplined about fat handling and still carry drug exposure through a product on the shelf.
The FTC Layer That Applies to Every Practice Advertisement
FDA is not the only regulator reading aesthetic marketing. The FTC’s Health Products Compliance Guidance, published in December 2022, applies alongside FDA jurisdiction, not instead of it.
Three points matter in dermatology. Claims are read for their express and implied meaning, so an image sequence can make a claim no sentence in the copy makes. Every objective health claim needs competent and reliable scientific evidence, and that substantiation must exist before the ad runs. Endorsements and testimonials count as the advertiser’s own claims, so a patient video describing a change in her scars is the practice’s claim to defend. Before and after galleries need clear and conspicuous disclosures.
What Adipose Derived Stem Cells Dermatology Research Supports in 2026
Candor protects the practice. No adipose-derived product is FDA approved for any skin indication. The published dermatologic work is preliminary, and registry activity is dominated by early phase, small, single site studies.
The correct framing for aesthetic dermatology regenerative medicine research is that it remains research. Clinicians reviewing the background on aesthetic medicine research reach the same conclusions: interest is genuine, evidence is preliminary, approval is absent. Adipose stem cells skin research is a field to follow, not a claim to make.
Dermatologist Adipose Banking in Daily Practice
Banking is the narrow and defensible activity here. Tissue is collected during a procedure the patient is already having, sent to a laboratory, and stored. No claim about a condition is made, and nothing is offered as therapy.
Save My Fat is a connector, not a provider. It does not collect, process, store, or treat. Practices evaluating the model usually begin with provider training requirements and with how the physician network is structured. Compliance is won or lost in the patient conversation, and guidance on introducing banking to patients keeps it on storage and regulatory reality. Dermatology stem cell banking in 2026 is a preservation decision, not a clinical one.
Frequently Asked Questions
What should dermatologists know about the current research on adipose-derived cells in skin conditions?
It is preliminary, and no adipose-derived product is FDA approved for any skin indication. Registry activity concentrates in early phase, small, single site safety and feasibility studies. Treat the literature as a reason to follow the field, not as support for a claim in a consultation or ad.
How can a dermatology practice discuss adipose banking with patients compliantly?
Describe what actually happens. Tissue is collected, sent to a laboratory, and stored for potential future participation in FDA-regulated pathways. State plainly that nothing is FDA approved, that eligibility and access cannot be guaranteed, and that evidence is preliminary. Document the conversation, and avoid connecting banking to any condition.
What are dermatologists legally allowed to say about ADSC research in aesthetic contexts?
You can describe published research accurately, including its phase, size, and limitations, and you can state that no product is approved. You cannot present research as an available option or imply benefit. FDA reads advertising as evidence of intended use, and the FTC requires substantiation for implied claims as well as express ones.
Where does adipose banking fit into a dermatology practice’s service offerings?
It sits beside a procedure the patient is already having, as a preservation choice. It is not a treatment offering or clinical care to be promoted as such. Practices that keep banking in the storage category, with a referral pathway and no claims attached, carry far less exposure.
What questions do dermatology patients commonly ask about banking?
Most ask what banking will allow them to do later, whether it is FDA approved, what it costs, and how long tissue can be stored. The accurate answers are that future use depends on regulatory status and physician judgment, and that no adipose-derived product is approved.
Does any exosome product have FDA approval for aesthetic or skin use?
No. FDA states in its consumer alert that no exosome product is FDA approved, and enforcement has followed. The May 2025 Supreme Rejuvenation letter cited exosome products as unapproved new drugs and unlicensed biologics, and exosome marketing was also flagged in the February 2026 Dynamic Stem Cell Therapy letter.
Key Takeaways
Regulatory clarity is the deliverable. Autologous fat grafting for contour is established surgical practice, and the analysis shifts only when tissue is processed beyond minimal manipulation or advertised for a purpose fat does not serve natively. All four criteria in 21 CFR 1271.10(a) must be met together, and autologous use alone satisfies just the fourth. The 2025 and 2026 warning letters show FDA applying that reasoning, and the exosome letters show a product on the shelf creating the same exposure.
The FTC guidance from December 2022 governs advertising, including before and after imagery and testimonials, and requires competent and reliable scientific evidence. No adipose-derived product is approved for any skin indication, and the published evidence is preliminary. Banking is storage and referral, nothing more, and it does not guarantee eligibility, access, or clinical benefit.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Practices weighing adipose tissue banking for potential future use can review current pricing, and referral questions can go to the Save My Fat team.
Save My Fat partners with L2 Bio for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including dermatology input is required before publication. Please consult your dermatologist before making any decisions about banking, treatment, or research participation.
About the author: Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent more than a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.
Related guide: the physician resource center.
